nach oben

Comparative Clinical Pathology

Erschienen in:

14.04.2016 | Original Article

Abnormal gene expression leads to poor prognosis in breast cancer patients in Bihar

verfasst von: Aseem Kumar Anshu, Akhileshwari Nath, Prinyanka, Neha Sinha, Priyanka Sinha, Shreya Sinha, J. K. Singh

Erschienen in: Comparative Clinical Pathology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

With its highest mortality rate, the breast cancer outruns other gynecological cancers. For a long time, the breast cancer was associated with poor prognosis. But with the advent of analysis of expression level of different protein receptors (ER/PR and Her-2/neu) with the help of immunohistochemistry (IHC) has ushered us to a new era of treatment of cancer called immunotherapy.

Tissues sampled from 167 breast cancer patients at pathology labs of Mahavir Cancer Institute & Research Center, S S Hospital and Research Institute and NMCH, Patna, Bihar, India, were processed by a routine protocol.

Highest percentage of patients showed ER⁺/PR+ and least percentage of patients were characterized by ER+/PR− (p value <0.0001, hazard ratio, 95 % CI 2.537–21.603). A large number of patients (52.09 %) were classified under luminal C. Interestingly, 25.74 and 44.31 % of total patients aged within 30–50 tend to show ER⁻/PR⁻ and Her-2/neu with p value <0.0081 (hazard ratio, 95 % CI 1.674–6.833) and 0.0313 (hazard ratio, 95 % CI 0.263–1.623), respectively.

The present endeavor was to classify the patients for their prognosis on the basis of hormonal and C-erb B2. The failure of the drug in ER−/PR− patients like tamoxifen is not a good sign to the oncologists. Herceptin on the other hand can play a good role in the treatment of greater percentage of patients showing Her-2/neu+. However, implementation of either new prognostic marker or more effective immunotherapy or both are warranted for effective treatment of breast cancer patients.

Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed

Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S et al (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:1340–1349PubMed

Baselga J, Seidman AD, Rosen PP et al (1997) Her-2 overexpression and paclitaxel sensitivity in breast cancer. Therapeutic implication. Oncology (Huntingt) 11(suppl 2):43–48

Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G et al (2000) HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18:3471–3479PubMed

Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S et al (1994) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137–144CrossRefPubMed

Carlomagno C, Perrone F, Gallo C et al (1996) c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702–2708PubMed

Coon JS, Marcus E, Gupta-Burt S et al (2002) Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061–1067PubMed

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429–4434CrossRefPubMed

Di Leo A, Gancberg D, Larsimont D et al (2002) Her-2 amplification and topoisomerase II α gene aberrations as predictive marker in node- positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-florouracil. Clin Cancer Res 8:1107–1116PubMed

Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM et al (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4:7–12PubMed

Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J et al (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89:111–117CrossRefPubMed

Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds (2013) Cancer incidence in five continents. Globocan, IARC. http://ci5.iarc.fr last accessed on [01-11-2013]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

Foulkes WD, Steffansson IM, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485CrossRefPubMed

Helsinki (2008) WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, 59th WMA General Assembly, Seoul

Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW (1999) Overexpression of c-erb B2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79:1220–1226CrossRefPubMedPubMedCentral

Huston JS, George AJ (2001) Engineered antibodies take center stage. Hum Antibodies 10:127–142PubMed

Kim R, Tanabe K, Uchida Y et al (2002) The role of Her-2 onco-protein in drug sensitivity in breast cancer (Review). Oncol Rep 9:3–9PubMed

Lakhani SR, Van DeVijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with BRCA1and BRCA2. JClin Oncol 20:2310–2318CrossRef

Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L et al (2002) Elevated serum HER-2/neu levels predict decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20:1467–1472CrossRefPubMed

Masood S, Bui MM (2002) Prognostic and predictive value of Her-2/neu oncogene in breast cancer. Microsc Res Tech 59:102–108CrossRefPubMed

McGuire WL, Chamness GC, Fuqua SA (1991) Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571–1577CrossRefPubMed

Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh LD et al (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Modern Pathol 17:1545–1554CrossRef

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMed

Dhillon PK (2003) Breast cancer factsheet. South Asia Network for Chronic Disease, Public Health Foundation of India., pp 1–22

Rilke F, Colnaghi MI, Cascinelli N et al (1991) Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44–49CrossRefPubMed

Ross JS, Fletcher JA, Linnette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325CrossRefPubMed

Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J (1998) Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462–469PubMed

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874CrossRefPubMedPubMedCentral

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423CrossRefPubMedPubMedCentral

Tagliabue E, Menard S, Robertson JF, Harris L (1999) c-erbB-2 expression in primary breast cancer. Int J Biol Markers 14:16–26PubMed

Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first line of treatment of Her-2 overexpressing metastatic breast cancer. J Clin Oncol 20:719–726CrossRefPubMed

Yamauchi H, O’Neill A, Gelman R et al (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of Her-2/c-neu protein. J Clin Oncol 15:2518–2525PubMed

Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W et al (2014) MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 9(5), e96228. doi:10.1371/journal.pone.0096228 CrossRefPubMedPubMedCentral

Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128CrossRefPubMed

Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A (2008) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20:628–635. doi:10.1093/annonc/mdn675, 2009CrossRefPubMed

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol vol 32(27):2959–2966CrossRef

Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K (1982) A prognostic index in primary breast cancer. Br J Cancer 45(3):361–366CrossRefPubMedPubMedCentral

Garner J, Goodfellow P (2004) The Nottingham Prognostic Index Questions for the MRCS vivas, Firstth edn., p 231

Titel: Abnormal gene expression leads to poor prognosis in breast cancer patients in Bihar
verfasst von: Aseem Kumar Anshu
Akhileshwari Nath
Prinyanka
Neha Sinha
Priyanka Sinha
Shreya Sinha
J. K. Singh
Publikationsdatum: 14.04.2016
Verlag: Springer London
Erschienen in: Comparative Clinical Pathology / Ausgabe 4/2016
Print ISSN: 1618-5641
Elektronische ISSN: 1618-565X
DOI: https://doi.org/10.1007/s00580-016-2261-x

Neu im Fachgebiet Pathologie

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Springer Medizin

Abnormal gene expression leads to poor prognosis in breast cancer patients in Bihar

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

The histomorphometric and histopathologic effect of methionine on the epidermis and dermis layers of skin in rat

Myiasis caused by Cephalopina titillator (Diptera: Oestridae) in camels (Camelus dromedarius) of semi-arid areas in Iran: distribution and associated risk factors

Pustular rumenitis associated with epithelial akeratosis, dyskeratosis, and parakeratosis in steers: report of two cases

Report of diabetes mellitus remission in a cat by orally administered glibenclamide

The protective effects of the methanolic root bark extract of Afzelia africana on conception and fetal development in diabetic female rats

Reference intervals for hematological and blood biochemistry reference values in healthy mules and hinnies

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie